LindaFayCarpenterMDMD(She/Her)
Psychiatry • Providence, RIPsychopharmacology
Professor, Psychiatry, Warren Alpert Medical School of Brown University
Dr. Carpenter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
345 Blackstone Blvd
Providence, RI 02906Phone+1 401-455-6200Fax+1 401-455-6309
Education & Training
Yale-New Haven Medical CenterResidency, Psychiatry, 1992 - 1997
Perelman School of Medicine at the University of PennsylvaniaClass of 1993
Penn Medical SchoolM.D., 1989 - 1992
Certifications & Licensure
RI State Medical License 1997 - 2026
PA State Medical License 1993 - 2018
CT State Medical License 1995 - 1997
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Eszopiclone Treatment & Cortisol Responsivity Start of enrollment: 2007 May 01
- Testosterone Antidepressant Augmentation in Women Start of enrollment: 2013 Aug 01
- Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Sep 12
- Join now to see all
Publications & Presentations
PubMed
- Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychoti...Victor M Tang, Scott Aaronson, Mohamed Abdelghani, Chris Baeken, Tracy Barbour
The American Journal of Psychiatry. 2025-03-19 - 1 citationsPsilocybin: From Psychiatric Pariah to Perceived Panacea.Gregory A Fonzo, Aaron S Wolfgang, Bryan R Barksdale, John H Krystal, Linda L Carpenter
The American Journal of Psychiatry. 2025-01-01 - The NExT trial: Protocol for a two-phase randomized controlled trial testing transcranial magnetic stimulation to augment exposure therapy for youth with OCD.Christine Conelea, Claire Breitenfeldt, Alixandra Wilens, Linda Carpenter, Benjamin Greenberg
Trials. 2024-12-18
Press Mentions
Ketamine Derivative OK’d by FDA Can Be a Wonder Drug for Some. Insurers Still Have to Catch UpFebruary 24th, 2025- Neurolief Presents Groundbreaking Study Results of Its Proliv™Rx Brain Neuromodulation Therapy for Treating Major Depression at the 7th Annual Neuropsychiatric Drug SummitOctober 8th, 2024
- Jolting the Brain’s Circuits with Electricity Is Moving from Radical to Almost Mainstream Therapy. Some Crucial Hurdles RemainJanuary 12th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
